ArticleCardiovascular and interventional radiology2025
Safety and Efficacy of Portal Vein Recanalization with Creation of Intrahepatic Portosystemic Shunt (PVR-TIPS) to Treat Chronic Portal Vein Thrombosis in Non-cirrhotic Patients.
Article in Cardiovascular and interventional radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Endovascular management of extrahepatic portal vein obstruction (EHPVO): expanding beyond surgical shunts.Abdominal radiology (New York) · 2026Review
- Outcomes of Transjugular Intrahepatic Portosystemic Shunt with Portal Vein Recanalization in Cirrhotic Patients with Acute Portal Vein Thrombosis: A Single-Center Study.Cardiovascular and interventional radiology · 2026Article
- Portal vein recanalization without TIPS via a submillimeter cavernomatous channel in non-cirrhotic extrahepatic portal vein obstruction.CVIR endovascular · 2026Article
- Percutaneous Recanalization of the Portal Vein in Children with Extrahepatic Portal Vein Obstruction.Cardiovascular and interventional radiology · 2026Article
- Navigating abdominal surgery in extrahepatic portal vein obstruction: new insights and remaining issues.Hepatobiliary surgery and nutrition · 2025Article
- Reply to "Prioritize Portal Vein Recanalization Without Transjugular Intrahepatic Portosystemic Shunt in Non-cirrhotic Extrahepatic Portal Vein Obstruction".Cardiovascular and interventional radiology · 2025Article
- Prioritize Portal Vein Recanalization Without Transjugular Intrahepatic Portosystemic Shunt in Non-cirrhotic Extrahepatic Portal Vein Obstruction.Cardiovascular and interventional radiology · 2025Article
- Portal Vein Recanalization with Creation of Intrahepatic Portosystemic Shunt (PVR-TIPS): Expanding the Limits of TIPS.Cardiovascular and interventional radiology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study assesses the efficacy and safety of Portal Vein Recanalization with Intrahepatic Portosystemic Shunt (PVR-TIPS) in non-cirrhotic patients with chronic portal vein occlusion (CPVO), cavernomatous transformation, and symptomatic portal hypertension (PH) and/or portal vein thrombotic progression. MATERIAL AND
methodsMedical records of 21 non-cirrhotic patients with CPVO and portal cavernoma undergoing PVR-TIPS were analyzed. Hemodynamic (intraprocedural reduction in portosystemic pressure gradient), clinical (data on gastrointestinal bleeding, abdominal pain, ascites, and presence of esophageal varices from imaging exams) and technical success (PVR-TIPS) assessed efficacy. Safety was determined through complications classified according to the CIRSE Classification System.
resultsPVR-TIPS was successfully performed in all patients, resulting in a significant reduction in portal pressure gradient by 10 mmHg (21.475 ± 9.7 mmHg - 11.454 ± 5,4 mmHg, p < 0.001), alleviating portal hypertension symptoms without thrombotic progression. Clinical success included resolution or reduction of ascites (p = 0.016), gastroesophageal varices (p = 0.004), abdominal pain (p = 0.0021), and cessation of gastrointestinal bleeding (p = 0.021). Complications occurred in 33% of patients, including six grade III events (1 perioperative liver bleeding, 5 delayed stent occlusions) and one grade VI event resulting in death (4.8%). Primary patency rate was 76% (21.3 months, range:0.2-82), secondary patency 100% (4 months, range:3.8-40.8). Survival at follow-up was 90.4%, with one unrelated death. One patient underwent liver transplantation, three became eligible post-recanalization.
conclusionPVR-TIPS proves effective and safe in reducing portal pressure gradient, thereby alleviating PH symptoms without evidence of portal thrombosis progression in non-cirrhotic patients with CPVO and portal cavernoma. It expands therapeutic options, including liver transplantation.
Indexed as
Identifiers
39789254What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.